Copyright
©The Author(s) 2023.
World J Gastroenterol. Feb 28, 2023; 29(8): 1304-1314
Published online Feb 28, 2023. doi: 10.3748/wjg.v29.i8.1304
Published online Feb 28, 2023. doi: 10.3748/wjg.v29.i8.1304
Ref. | N | Location | Outcome |
Tan et al[87] | 3399 | North America, Europe, and Asia | Patient with PTEN mutations possess a lifetime breast cancer risk of 85%, thyroid cancer risk of 35%, renal cell carcinoma of 35%, endometrial cancer risk of 28%, colorectal cancer risk of 9%, and melanoma risk of 6% |
Fackenthal et al[88] | 2 | United States | There is an increased risk of male breast cancer in patient with PTEN mutations and CS |
Harach et al[89] | 11 | Argentina | Patients with CS have increased likelihood of developing benign thyroid lesions, with increased risk of malignant transformation |
Ngeow et al[90] | 2723 | United States | CS and CS-like phenotypes possess standardized incidence rate for thyroid cancer of 72%, particularly follicular thyroid cancer |
Heald et al[91] | 127 | North America and Europe | PTEN mutations are associated with early-onset (age < 50) colorectal malignancy; routine colonoscopy should be encouraged |
- Citation: Gorji L, Albrecht P. Hamartomatous polyps: Diagnosis, surveillance, and management. World J Gastroenterol 2023; 29(8): 1304-1314
- URL: https://www.wjgnet.com/1007-9327/full/v29/i8/1304.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i8.1304